Valaciclovir for Epstein-Barr Virus Suppression in Moderate-to-Severe COPD: A Randomized Double-Blind Placebo-Controlled Trial. (2023)
Attributed to:
The role of Cathepsin S in PAR-1 mediated lung inflammation - a new paradigm for neutrophilic inflammation
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.chest.2023.03.040
PubMed Identifier: 37011709
Publication URI: http://europepmc.org/abstract/MED/37011709
Type: Journal Article/Review
Volume: 164
Parent Publication: Chest
Issue: 3
ISSN: 0012-3692